Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that sits at the intersection of energy metabolism, DNA repair and cellular signaling. Because its concentration falls in aging tissues across multiple organisms, NAD+ has become a central variable in laboratory research on the biology of aging and longevity pathways.

Why NAD+ sits at the center of aging biology

NAD+ is best known as an electron carrier: in its oxidized (NAD+) and reduced (NADH) forms it shuttles reducing equivalents through glycolysis, the tricarboxylic acid cycle and oxidative phosphorylation. That redox role alone would make it indispensable. What has drawn aging researchers to NAD+, however, is a second, non-redox function — NAD+ is consumed as a substrate by enzymes that regulate chromatin, repair DNA and coordinate immune signaling.¹ In these reactions NAD+ is not merely recycled between oxidized and reduced states; it is cleaved, and its nicotinamide moiety is released, meaning the cell must continually resynthesize it.

A recurring observation across model organisms is that tissue and cellular NAD+ concentrations decline gradually with age. Reviews of the field describe this decrement in rodents and, from cross-sectional measurements, in human tissues, and link it correlatively to several aging-associated conditions studied in the laboratory.¹² It is important to frame this precisely: much of the causal work rests on genetically or pharmacologically manipulated animals and cultured cells. The association between lower NAD+ and functional decline is well documented preclinically; the extent to which it drives aging in humans remains an open research question.

NAD+ metabolism: synthesis, salvage and age-related decline

Cells maintain NAD+ through three biosynthetic routes. The de novo pathway builds NAD+ from the amino acid tryptophan. The Preiss–Handler pathway uses dietary nicotinic acid. The salvage pathway recycles nicotinamide — the very by-product released when sirtuins, PARPs and CD38 cleave NAD+ — back into the nucleotide, and also processes the precursors nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).¹ In most mammalian tissues the salvage pathway carries the largest share of flux, and its rate-limiting enzyme is nicotinamide phosphoribosyltransferase (NAMPT).

The age-related fall in NAD+ appears to result from pressure on both sides of the ledger. On the supply side, NAMPT expression and salvage capacity decrease in several tissues. Studies in which NAMPT is deleted from mouse skeletal muscle produced an approximately 85% collapse in intramuscular NAD+ accompanied by progressive fiber degeneration and loss of strength and endurance — a dramatic demonstration that salvage flux is required to sustain the muscle NAD+ pool.³ On the demand side, consumption rises: the NAD+-degrading enzyme CD38 increases in expression and activity with age.⁴

The physiological reading of this imbalance is that a shrinking NAD+ pool constrains redox-dependent metabolism and, simultaneously, the non-redox enzymes that depend on NAD+ as a substrate. In experimental systems this manifests as reduced mitochondrial respiration, altered energy metabolism and diminished stress resilience.² These are observations from models and cultured cells, not clinical endpoints.

The enzymes that consume NAD+: sirtuins, PARPs and CD38

Three enzyme families draw on the same NAD+ pool, which is why their activities are metabolically coupled. Understanding them is central to why NAD+ availability is treated as a node in longevity-pathway research.

Sirtuins

Sirtuins (SIRT1–SIRT7 in mammals) are NAD+-dependent deacylases that remove acetyl and related acyl groups from histones and other proteins. Through this activity they influence chromatin structure, gene expression, DNA-repair coordination and mitochondrial function. Because each catalytic cycle requires an NAD+ molecule, sirtuin activity is sensitive to NAD+ concentration — a mechanistic link that has been developed over years of work connecting the SIR2 family to metabolism and aging in model organisms.⁵ When NAD+ falls, sirtuin output is predicted to fall with it, a relationship repeatedly examined in rodent and cell studies.¹

PARPs

Poly(ADP-ribose) polymerases (PARPs), chiefly PARP1, detect DNA strand breaks and consume large quantities of NAD+ to build poly(ADP-ribose) chains during repair. Under genotoxic stress — which accumulates with age — PARP overactivation can deplete NAD+ substantially, placing PARP-mediated DNA repair in direct competition with sirtuins for a shared, finite pool.² This competition is one of the more mechanistically satisfying explanations for why genomic instability and metabolic decline tend to travel together in aging tissue.

CD38

CD38 is an NADase expressed prominently on immune cells. In mouse tissue, CD38 expression and activity climb with age, and CD38-knockout animals are protected from the age-related NAD+ decline. Work using these models identified CD38 as a principal driver of tissue NAD+ loss and of mitochondrial dysfunction through a SIRT3-dependent mechanism; the same studies flagged CD38 as the main enzyme degrading the precursor NMN in vivo, a detail with direct implications for how precursor-based strategies are designed.⁴

Mitochondria deserve a specific mention here. NAD+ is required for oxidative phosphorylation and ATP production, and mitochondrial NAD+ pools are regulated somewhat separately from cytosolic ones. Because mitochondrial-derived signaling is itself an active area of longevity research, peptides that act on mitochondrial pathways — for example those investigated in MOTS-C studies — are often examined alongside NAD+ metabolism in the same experimental frameworks. The unifying theme is that mitochondrial function and NAD+ availability are difficult to separate.

NAD+, cellular senescence and inflammaging

Cellular senescence — a durable arrest of cell division accompanied by a distinctive secretory program — is one of the most studied hallmarks of aging, and it connects to NAD+ through inflammation. Senescent cells release a mixture of pro-inflammatory cytokines, chemokines and proteases collectively termed the senescence-associated secretory phenotype (SASP).

A 2020 study traced a specific mechanistic loop between senescence and NAD+ decline. As tissues age, senescent cells accumulate in visceral adipose tissue and liver; their SASP signals drive resident macrophages to proliferate and to upregulate CD38. These CD38-high, pro-inflammatory macrophages then consume NAD+ more aggressively, lowering tissue levels further.⁶ In other words, senescence and NAD+ loss can reinforce one another: inflammation raises NAD+ consumption, and constrained NAD+ compromises the very repair and metabolic functions that might otherwise limit further damage. This self-amplifying character — often described under the umbrella term "inflammaging" — is why the NAD+–CD38–senescence axis is treated as a candidate lever in aging research rather than a single-node pathway.

The evidence base here is again predominantly murine and cell-based. The macrophage–CD38 loop was defined in mice, and its quantitative relevance to human tissue aging is still being characterized.

Restoring NAD+ in experimental models

If declining NAD+ contributes causally to aging phenotypes in animals, then raising it should attenuate some of them — and in rodents, precursor supplementation frequently does. Comprehensive reviews of the in vivo literature report that boosting NAD+ with NR or NMN improved mitochondrial function, insulin sensitivity and several tissue-level aging markers across a range of mouse models.⁷ The NAMPT-deletion muscle model discussed earlier is instructive in both directions: depleting NAD+ caused degeneration, and administering NR rapidly ameliorated the functional deficits and restored muscle mass.³

Two caveats keep this from being a simple story. First, reported lifespan effects in mammals are modest and depend heavily on strain, sex, dose and the age at which intervention begins — median-lifespan extensions in animal studies are measured in single-digit-to-low-double-digit percentages under favorable conditions, not the dramatic reversals sometimes implied in popular coverage. Second, longevity mechanisms interact. Work on mitonuclear protein imbalance and the mitochondrial unfolded protein response showed that several distinct interventions — including NAD+-linked and non-NAD+ compounds such as rapamycin and resveratrol — can extend lifespan in C. elegans through overlapping mitochondrial stress pathways.⁸ NAD+ is one input into a networked system, not an isolated switch.

Pharmacological strategies aimed at the demand side complement precursor supply. Because CD38 is a major NAD+ consumer that rises with age, inhibiting or genetically removing it preserves NAD+ and mitochondrial function in mouse tissue.⁴ This positions CD38 inhibition and precursor supplementation as two conceptually different but potentially complementary experimental approaches to the same pool.

What human trials have and have not shown

The translation from mouse to human is where enthusiasm meets uncertainty. On the pharmacokinetic question — do oral precursors actually raise NAD+ in people? — the answer is reasonably clear. A first-in-human pharmacokinetic study showed that single oral doses of NR produced dose-dependent increases in the blood NAD+ metabolome, establishing NR as orally bioavailable in humans.⁹ Later controlled trials of NMN similarly reported elevated circulating NAD+ metabolites after weeks of supplementation.¹⁰

On functional outcomes, the human record is mixed. A randomized, placebo-controlled trial of NR (2000 mg/day for 12 weeks) in obese, insulin-resistant men reported no serious adverse events and normal safety bloods, but found no improvement in insulin sensitivity, energy expenditure or body composition.¹¹ By contrast, a randomized, placebo-controlled trial of NMN in postmenopausal women with prediabetes reported an increase in skeletal-muscle insulin sensitivity and insulin signaling.¹⁰ A separate NMN trial found the supplement was well tolerated over 12 weeks and raised serum nicotinamide, with only a non-significant trend toward reduced arterial stiffness.¹²

Read together, these trials support two honest conclusions and no more: oral NR and NMN reliably raise NAD+ metabolites and have been well tolerated at the doses and durations tested, but demonstrable functional benefits are inconsistent and population-dependent. Larger, longer trials with clinical endpoints would be required before any statement about human aging outcomes could be made — and NAD+ precursors remain dietary or investigational compounds, not approved therapeutics.

Open questions and research context

Several questions keep NAD+ an active rather than settled field. How faithfully does the rodent NAD+ decline map onto human tissues, given the difficulty of measuring intracellular NAD+ in living people? Which tissues and cell types benefit most from raising NAD+, and does systemic supplementation reach them? How do the competing demands of sirtuins, PARPs and CD38 resolve under different physiological conditions? And can demand-side approaches, such as CD38 modulation, outperform or complement precursor supply?¹⁴ These are the kinds of questions that laboratory-grade reagents are used to probe.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.